AI Analysis of Cancer Mutations may Improve Therapy

Cancer has many faces - no wonder, then, that the range of cancer-causing mutations is huge as well. The totality of such genomic alterations in an individual is what experts call a "mutational landscape." These landscapes differ from one another depending on the type of cancer. And even people suffering from the same cancer often have different mutation patterns.

Researchers have already catalogued the mutational landscapes of numerous types of cancer. Somatic structural variants (SVs) have been shown to account for more than half of all cancer-driving mutations. These are those mutations in cells that emerge over the course of life - such as when copying errors creep into the DNA during cell division - and thereby alter the chromosome structure. They are not inherited and are found only in affected cells and in their daughter cells. As we age, such genomic alterations become more numerous, and a person's mutational landscape increasingly comes to resemble a unique mosaic.

Although somatic SVs play a crucial role in cancer development, relatively little is known about them. "There is a lack of methods that analyze their effects on cell function," explains Dr. Ashley Sanders, who heads the Genome Stability and Somatic Mosaicism Lab at the Max Delbrück Center. That's changing thanks to new research findings, which Sanders recently published in the journal Nature Biotechnology along with the European Molecular Biology Laboratory (EMBL). "We developed a computational analysis method to detect and identify the functional effects of somatic SVs," she reports. This enabled the team to understand the molecular consequences of individual somatic mutations in different leukemia patients, giving them new insights into the mutation-specific alterations. Sanders says it may also be possible to use these findings to develop therapies that target the mutated cells, adding that “they open up exciting new avenues for personalized medicine."

Their calculations are based on data from Strand-seq - a special single-cell sequencing method that Sanders played an instrumental role in developing and that was first introduced to the scientific community in 2012. This technique can examine a cell’s genome in much greater detail than conventional single-cell sequencing technologies. Thanks to a sophisticated experimental protocol, the Strand-seq method can independently analyze the two parental DNA strands (one from the father and one from the mother). With conventional sequencing methods, distinguishing such homologs - chromosomes that are similar in shape and structure but not identical - is nearly impossible. "By resolving the individual homologs within a cell, somatic SVs can be identified much better than with other methods," explains Sanders. The approach used for doing this was described by the researcher and her colleagues in a paper that appeared in Nature Biotechnology in 2020.

The research team is part of the joint research focus “Single-Cell Approaches for Personalized Medicine” of the Berlin Institute of Health at Charité (BIH), Charité - Universitätsmedizin Berlin, and the Max Delbrück Center.

Building on this work, they are now able to also determine the positions of nucleosomes in each cell. Nucleosomes are units of DNA wrapped around protein complexes called histones, and play a crucial role in organizing chromosomes. The position of nucleosomes can change during gene expression, with the type of wrapping revealing whether or not a gene is active. Sanders and her colleagues developed a self-learning algorithm to compare the gene activity of patient cells with and without somatic SV mutations, allowing them to determine the molecular impact of the structural variants.

"We can now take a sample from a patient, look for the mutations that led to the disease, and also learn the signaling pathways that the disease-causing mutations disrupt," explains Sanders. For example, the team was able to identify a rare but very aggressive mutation in a leukemia patient. The nucleosome analysis provided the researchers with information about the signaling pathways involved, which they used to specifically inhibit the growth of cells containing the mutation. "This means that a single test tells us something about the cellular mechanisms involved in cancer formation," says Sanders. "We can eventually use this knowledge to develop personalized treatments, guided by each patient’s unique condition."

Jeong H, Grimes K, Rauwolf KK, Bruch PM, Rausch T, Hasenfeld P, Benito E, Roider T, Sabarinathan R, Porubsky D, Herbst SA, Erarslan-Uysal B, Jann JC, Marschall T, Nowak D, Bourquin JP, Kulozik AE, Dietrich S, Bornhauser B, Sanders AD, Korbel JO.
Functional analysis of structural variants in single cells using Strand-seq.
Nat Biotechnol. 2022 Nov 24. doi: 10.1038/s41587-022-01551-4

Most Popular Now

Bayer Launches New Healthy-Aging Ecosyst…

Combining a scientifically formulated dietary supplement, a leading-edge wellness companion app, and a saliva-based a biological age test by Chronomics, Bayer is taking a big step in the emerging healthy-aging...

Airwave Healthcare Expands Team with Fra…

Patient stimulus technology provider Airwave Healthcare has appointed Francesca McPhail, who will help health and care providers achieve more from their media and entertainment systems for people receiving care. Francesca McPhail...

Scientists Use AI to Detect Chronic High…

Researchers at Klick Labs unveiled a cutting-edge, non-invasive technique that can predict chronic high blood pressure (hypertension) with a high degree of accuracy using just a person's voice. Just published...

New AI-Driven Tool could Revolutionize B…

Researchers at the Icahn School of Medicine at Mount Sinai have developed a noninvasive technique that could dramatically improve the way doctors monitor intracranial hypertension, a condition where increased pressure...

ChatGPT Outperformed Trainee Doctors in …

The chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma and chest infections in a study presented at...

Former NHS CIO Will Smart Joins Alcidion

A former national chief information officer for health and social care in England, Will Smart will join the Alcidion Group board in a global role from October. He will provide...

The Darzi Review: The NHS "Is in Se…

Lyn Whitfield, content director at Highland Marketing, takes a look at Lord Darzi's review of the NHS, immediate reaction, and next steps. The review calls for a "tilt towards technology...

Can Google Street View Data Improve Publ…

Big data and artificial intelligence are transforming how we think about health, from detecting diseases and spotting patterns to predicting outcomes and speeding up response times. In a new study analyzing...

Healthcare Week Luxembourg: Second Editi…

1 - 2 October 2024, Luxembourg.Save the date: Healthcare Week Luxembourg is back on 1 and 2 October 2024 at Luxexpo The Box. Acclaimed last year by healthcare professionals from...

SPARK TSL Appoints David Hawkins as its …

SPARK TSL has appointed David Hawkins as its new sales director, to support take-up of the SPARK Fusion infotainment solution by NHS trusts and health boards. SPARK Fusion is a state-of-the-art...

AI Products Like ChatGPT can Provide Med…

The much-hyped AI products like ChatGPt may provide medical doctors and healthcare professionals with information that can aggravate patients' conditions and lead to serious health consequences, a study suggests. Researchers considered...

One in Five UK Soctors use AI Chatbots

A survey led by researchers at Uppsala University in Sweden reveals that a significant proportion of UK general practitioners (GPs) are integrating generative AI tools, such as ChatGPT, into their...